<PAGE> 1
OMB APPROVAL
OMB Number: 3235-0145
Expires: December 31, 1999
Estimated average burden
hours per response . . .14.90
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*
Cantab Pharmaceuticals plc
(Name of Issuer)
American Depositary Shares representing
Ordinary Shares, par value pound sterling.02 per share
(Title of Class of Securities)
138084108
(CUSIP Number)
December 31, 1998
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
/ / Rule 13d-1(b)
/ / Rule 13d-1(c)
/x/ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
Page 1 of 8 pages
<PAGE> 2
CUSIP NO. 138084108 13G PAGE 2 OF 8 PAGES
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Biotechnology Venture Fund, S.A. (i.l.)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
3,208,327
NUMBER OF
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY -0-
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 3,208,327
WITH 8 SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,849,999 Ordinary Shares (see Item 4(a) of attached Schedule)
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / /
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.3%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 2 of 8 pages
<PAGE> 3
CUSIP NO. 138084108 13G PAGE 3 OF 8 PAGES
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Tetraven Fund S.A. (i.l.)
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg
- --------------------------------------------------------------------------------
5 SOLE VOTING POWER
641,672
NUMBER OF
SHARES 6 SHARED VOTING POWER
BENEFICIALLY
OWNED BY -0-
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 641,672
WITH 8 SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,849,999 Ordinary Shares (see Item 4(a) of attached Schedule)
- --------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / /
- --------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.3%
- --------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON *
CO
- --------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 3 of 8 pages
<PAGE> 4
ITEM 1(a). Name of Issuer: Cantab Pharmaceuticals plc.
ITEM 1(b). Address of Issuer's Principal Executive Offices:
184 Cambridge Science Park, Milton Road, Cambridge CB4 4GN
United Kingdom.
ITEM 2(a). Name of Person Filing: Biotechnology Venture Fund,
S.A. (i.l.) ("Biotechnology") and Tetraven Fund S.A. (i.l.)
("Tetraven").
ITEM 2(b). Address of Principal Business Office or, if None, Residence:
The address of the principal business office of Biotechnology
and Tetraven is 231 Val des Bons Malades, L-2121
Luxembourg-Kirchberg.
ITEM 2(c). Citizenship: Each of Biotechnology and Tetraven is a
corporation organized under the laws of Luxembourg.
ITEM 2(d). Title of Class of Securities: American Depositary Shares
representing Ordinary Shares, par value pound sterling.02 per
share ("Ordinary Shares").
ITEM 2(e). CUSIP Number: 138084108.
ITEM 3. If this statement is filed pursuant to Rules 13d-1(b), or
13d-2(b), check whether the person filing is a:
(a) / / Broker or Dealer registrered under Section 15 of the
Securities Exchange Act of 1934 (the "Act");
(b) / / Bank as defined in Section 3(a)(6) of the Act;
(c) / / Insurance Company as defined in Section 3(a)(19) of
the Act;
(d) / / Investment Company registered under Section 8 of the
Investment Company Act of 1940;
(e) / / An investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E);
(f) / / An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F);
(g) / / A parent holding company or control person in
accordance with Rule 13d-1(b)(1)(ii)(G);
(h) / / A savings association as defined in Section 3(b) of
the Federal Deposit Insurance Act;
(i) / / A church plan that is excluded from the definition of
an investment company under Section 3(c)(14) of the Investment
Company Act;
(j) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(J);
If this statement is filed pursuant to Rule 13d-1(c), check
this box. / /
Not applicable. This statement on Schedule 13G is not filed
pursuant to Rule 13d-1(b), Rule 13d-1(c) or Rule 13d-2(b).
Page 4 of 8 pages
<PAGE> 5
ITEM 4. Ownership.
(a) Amount Beneficially Owned: Each of Biotechnology and
Tetraven may be deemed to beneficially own 3,848,999
Ordinary Shares as of December 31, 1998.
Biotechnology was the record owner of 3,208,327
Ordinary Shares as of December 31, 1998. Tetraven was
the record owner of 641,672 Ordinary Shares as of
December 31, 1998. (The shares held of record by
Biotechnology and Tetraven are referred to
collectively herein as the "Record Shares.") By
virtue of their relationship as affiliated
corporations with the same individuals as
liquidators, each of Biotechnology and Tetraven may
be deemed to beneficially own all of the Record
Shares. Hence, each of Biotechnology and Tetraven may
be deemed to beneficially own 3,848,999 Ordinary
Shares as of December 31, 1998.
All of the additional Ordinary Shares acquired by
Biotechnology and Tetraven since the filing of
Amendment No. 1 to Schedule 13G, dated February 13,
1998, were acquired in connection with the Issuer's
stock split.
(b) Percent of Class: Biotechnology: 9.3%; Tetraven:
9.3%.
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
Biotechnology: 3,208,327 Ordinary Shares;
Tetraven: 641,672 Ordinary Shares.
(ii) shared power to vote or to direct the vote:
Biotechnology: 0 Ordinary Shares; Tetraven:
0 Ordinary Shares.
(iii) sole power to dispose or to direct the
disposition of: Biotechnology: 3,208,327
Ordinary Shares; Tetraven: 641,672 Ordinary
Shares.
(iv) shared power to dispose or to direct the
disposition of: Biotechnology: 0 Ordinary
Shares; Tetraven: 0 Ordinary Shares.
Each of Biotechnology and Tetraven expressly disclaims
beneficial ownership of any Ordinary Shares of Cantab
Pharmaceuticals plc, except, in the case of Biotechnology, for
the 3,208,327 Ordinary Shares that it holds of record and, in
the case of Tetraven, for the 641,672 Ordinary Shares that it
holds of record.
ITEM 5. Ownership of Five Percent or Less of a Class:
Not applicable.
ITEM 6. Ownership of More than Five Percent on Behalf of Another
Person:
Not applicable.
ITEM 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent
Holding Company:
Page 5 of 8 pages
<PAGE> 6
Not applicable.
ITEM 8. Identification and Classification of Members of the Group:
Not applicable
ITEM 9. Notice of Dissolution of Group:
Not applicable.
ITEM 10. Certification:
Not applicable. This statement on Schedule 13G is not filed
pursuant to Rule 13d-1(b).
Page 6 of 8 pages
<PAGE> 7
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief,
each of the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Date: February 9, 1999
BIOTECHNOLOGY VENTURE FUND, S.A. (i.l.)
By: /s/M. Rose DOCK
Name: M. Rose DOCK
Title: Liquidator
By: /s/Fernand HEIM
Name: Fernand HEIM
Title: Mandatory
TETRAVEN FUND S.A. (i.l.)
By: /s/M. Rose DOCK
Name: M. Rose DOCK
Title: Liquidator
By: /s/Fernand HEIM
Name: Fernand HEIM
Title: Mandatory
Page 7 of 8 pages
<PAGE> 8
Exhibit 1
AGREEMENT
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934,
the undersigned hereby agree that only one statement containing the information
required by Schedule 13G need be filed with respect to the ownership by each of
the undersigned of shares of stock of Cantab Pharmaceuticals plc.
This Agreement may be executed in any number of counterparts, each of
which shall be deemed an original.
EXECUTED this 9th day of February, 1999.
BIOTECHNOLOGY VENTURE FUND, S.A. (i.l.)
By: /s/M. Rose DOCK
Name: M. Rose DOCK
Title: Liquidator
By: /s/Fernand HEIM
Name: Fernand HEIM
Title: Mandatory
TETRAVEN FUND S.A. (i.l.)
By: /s/M. Rose DOCK
Name: M. Rose DOCK
Title: Liquidator
By: /s/Fernand HEIM
Name: Fernand HEIM
Title: Mandatory
Page 8 of 8 pages
